UCB shares dip as investors worry forecast may be too optimistic despite Bimzelx sales beat
read at Endpoints ↗EarningsNegative
UCB reported that sales of its lead drug Bimzelx exceeded analysts' expectations for the quarter.
However, the company also gave a full-year revenue outlook that some investors view as overly optimistic.
The mixed signals led to a decline in UCB’s share price on Thursday, with the stock falling despite the positive sales number.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “UCB's stock slides despite Bimzelx revenue beating forecasts”
read at Endpoints ↗95 words · retrieved Jul 30
comments(0)
5-min edit window · permanent after that